

Leen Delang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6642200/publications.pdf>

Version: 2024-02-01

90
papers

4,409
citations

136740

32
h-index

128067

60
g-index

109
all docs

109
docs citations

109
times ranked

7754
citing authors

#	ARTICLE	IF	CITATIONS
1	Animal models for COVID-19. <i>Nature</i> , 2020, 586, 509-515.	13.7	705
2	Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. <i>Antiviral Research</i> , 2018, 153, 85-94.	1.9	295
3	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2 [~] infected hamsters, whereas hydroxychloroquine lacks activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26955-26965.	3.3	240
4	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. <i>Nature Communications</i> , 2020, 11, 5838.	5.8	225
5	Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein. <i>Cell Reports</i> , 2015, 10, 600-615.	2.9	201
6	Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2770-2784.	1.3	187
7	Stable distinct core eukaryotic viromes in different mosquito species from Guadeloupe, using single mosquito viral metagenomics. <i>Microbiome</i> , 2019, 7, 121.	4.9	109
8	Statins potentiate the <i>in vitro</i> anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. <i>Hepatology</i> , 2009, 50, 6-16.	3.6	104
9	Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. <i>EBioMedicine</i> , 2021, 68, 103403.	2.7	102
10	The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. <i>Scientific Reports</i> , 2016, 6, 31819.	1.6	88
11	Prostratin and 12-O-Tetradecanoylphorbol 13-Acetate Are Potent and Selective Inhibitors of Chikungunya Virus Replication. <i>Journal of Natural Products</i> , 2012, 75, 2183-2187.	1.5	87
12	Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus. <i>Antiviral Research</i> , 2013, 98, 12-18.	1.9	87
13	Towards antivirals against chikungunya virus. <i>Antiviral Research</i> , 2015, 121, 59-68.	1.9	84
14	Recent African strains of Zika virus display higher transmissibility and fetal pathogenicity than Asian strains. <i>Nature Communications</i> , 2021, 12, 916.	5.8	80
15	The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. <i>Hepatology</i> , 2013, 57, 492-504.	3.6	66
16	Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication. <i>Journal of Natural Products</i> , 2015, 78, 1277-1283.	1.5	62
17	Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase. <i>Journal of Virology</i> , 2017, 91, .	1.5	62
18	The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. <i>Biochemical Pharmacology</i> , 2012, 84, 1400-1408.	2.0	61

#	ARTICLE	IF	CITATIONS
19	Identification of [1,2,3]Triazolo[4,5-d]pyrimidin-7(6H)-ones as Novel Inhibitors of Chikungunya Virus Replication. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4000-4008.	2.9	60
20	The future of antivirals. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 596-602.	1.3	56
21	Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4103-4113.	1.4	54
22	Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7782-7785.	1.4	54
23	Tigliane diterpenes from <i>Croton mauritianus</i> as inhibitors of chikungunya virus replication. <i>FÅ-toterapÅ-Åç</i> , 2014, 97, 87-91.	1.1	50
24	Antiviral activity of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones against chikungunya virus targeting the viral capping nsP1. <i>Antiviral Research</i> , 2017, 144, 216-222.	1.9	44
25	Structure-activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6014-6025.	1.4	43
26	Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. <i>Antiviral Research</i> , 2017, 140, 37-44.	1.9	43
27	Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. <i>Nature Communications</i> , 2020, 11, 4253.	5.8	43
28	Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals. <i>Antiviral Research</i> , 2017, 145, 82-86.	1.9	41
29	CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer. <i>Experimental Cell Research</i> , 2018, 372, 168-177.	1.2	41
30	An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. <i>Science Translational Medicine</i> , 2021, 13, eabi7826.	5.8	41
31	Chikungunya virus infections: time to act, time to treat. <i>Current Opinion in Virology</i> , 2017, 24, 25-30.	2.6	39
32	Medical treatment options for COVID-19. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 209-214.	0.4	39
33	A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. <i>PLoS Biology</i> , 2019, 17, e3000281.	2.6	36
34	Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. <i>Viruses</i> , 2010, 2, 826-866.	1.5	35
35	Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 327-337.	1.4	34
36	Antiplasmodial, anti-chikungunya virus and antioxidant activities of 64 endemic plants from the Mascarene Islands. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 622-628.	1.1	32

#	ARTICLE	IF	CITATIONS
37	Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection. <i>Antiviral Research</i> , 2018, 149, 113-117.	1.9	30
38	Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway. <i>Journal of Natural Products</i> , 2016, 79, 680-684.	1.5	28
39	Antiviral Compounds from <i>Codiaeum peltatum</i> Targeted by a Multi-informative Molecular Networks Approach. <i>Journal of Natural Products</i> , 2019, 82, 330-340.	1.5	28
40	Hepatitis C Virus-Specific Directly Acting Antiviral Drugs. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 289-320.	0.7	27
41	Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid. <i>PLoS Pathogens</i> , 2019, 15, e1007760.	2.1	26
42	Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	25
43	Antiviral Strategies Against Chikungunya Virus. <i>Methods in Molecular Biology</i> , 2016, 1426, 243-253.	0.4	24
44	Reaching beyond HIV/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus. <i>RSC Advances</i> , 2015, 5, 85938-85949.	1.7	21
45	Chikungunya virus drug discovery: still a long way to go?. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 855-866.	2.5	21
46	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. <i>EBioMedicine</i> , 2021, 66, 103288.	2.7	21
47	Protein kinases C as potential host targets for the inhibition of chikungunya virus replication. <i>Antiviral Research</i> , 2017, 139, 79-87.	1.9	20
48	Rational modifications on a benzylidene-acrylohydrazide antiviral scaffold, synthesis and evaluation of bioactivity against Chikungunya virus. <i>European Journal of Medicinal Chemistry</i> , 2018, 149, 56-68.	2.6	20
49	Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 349-368.	2.9	20
50	Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase. <i>Antiviral Research</i> , 2012, 93, 30-38.	1.9	19
51	Establishment of <i>Culex modestus</i> in Belgium and a Glance into the Virome of Belgian Mosquito Species. <i>MSphere</i> , 2021, 6, .	1.3	19
52	Optimization of a Class of Tryptophan Dendrimers That Inhibit HIV Replication Leads to a Selective, Specific, and Low-Nanomolar Inhibitor of Clinical Isolates of Enterovirus A71. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5064-5067.	1.4	18
53	Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones. <i>ACS Infectious Diseases</i> , 2018, 4, 605-619.	1.8	18
54	Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1400-1416.	2.9	17

#	ARTICLE	IF	CITATIONS
55	In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. <i>Journal of Hepatology</i> , 2012, 56, 41-48.	1.8	16
56	Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death. <i>Journal of Natural Products</i> , 2016, 79, 675-679.	1.5	16
57	Design, synthesis and evaluation against Chikungunya virus of novel small-molecule antiviral agents. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 869-874.	1.4	16
58	Identification of 2-(4-(Phenylsulfonyl)piperazine-1-yl)pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 906-912.	1.3	16
59	Understanding the Mechanisms Underlying Host Restriction of Insect-Specific Viruses. <i>Viruses</i> , 2020, 12, 964.	1.5	15
60	Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	15
61	New class of early-stage enterovirus inhibitors with a novel mechanism of action. <i>Antiviral Research</i> , 2017, 147, 67-74.	1.9	14
62	Antiviral drug discovery against arthritogenic alphaviruses: Tools and molecular targets. <i>Biochemical Pharmacology</i> , 2020, 174, 113777.	2.0	14
63	Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors. <i>Microorganisms</i> , 2021, 9, 734.	1.6	13
64	Are statins a viable option for the treatment of infections with the hepatitis C virus?. <i>Antiviral Research</i> , 2014, 105, 92-99.	1.9	12
65	Antiviral Strategies against Arthritogenic Alphaviruses. <i>Microorganisms</i> , 2020, 8, 1365.	1.6	12
66	Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism. <i>Biochemical Pharmacology</i> , 2016, 120, 15-21.	2.0	11
67	A Viral Polymerase Inhibitor Reduces Zika Virus Replication in the Reproductive Organs of Male Mice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2122.	1.8	11
68	Comparative analysis of the molecular mechanism of resistance to vapendavir across a panel of picornavirus species. <i>Antiviral Research</i> , 2021, 195, 105177.	1.9	10
69	Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10833-10847.	2.9	9
70	Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum. <i>Antiviral Research</i> , 2019, 168, 210-214.	1.9	9
71	Structural Insights into the Mechanisms of Action of Functionally Distinct Classes of Chikungunya Virus Nonstructural Protein 1 Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0256620.	1.4	9
72	Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains. <i>Vaccine</i> , 2017, 35, 1370-1372.	1.7	8

#	ARTICLE	IF	CITATIONS
73	Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by <i>Aedes</i> Mosquitoes. <i>MSphere</i> , 2018, 3, .	1.3	8
74	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. <i>Antiviral Research</i> , 2022, 202, 105311.	1.9	8
75	Antiviral effects of selected nucleoside analogues against human parechoviruses A1 and A3. <i>Antiviral Research</i> , 2019, 162, 51-53.	1.9	6
76	Assessing <i>In Vitro</i> Resistance Development in Enterovirus A71 in the Context of Combination Antiviral Treatment. <i>ACS Infectious Diseases</i> , 2021, 7, 2801-2806.	1.8	6
77	Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 215-224.	1.8	5
78	PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3375-3384.	1.3	4
79	Favipiravir Does Not Inhibit Chikungunya Virus Replication in Mosquito Cells and <i>Aedes aegypti</i> Mosquitoes. <i>Microorganisms</i> , 2021, 9, 944.	1.6	4
80	Posaconazole inhibits multiple steps of the alphavirus replication cycle. <i>Antiviral Research</i> , 2022, 197, 105223.	1.9	4
81	Selecting and Characterizing Drug-Resistant Hepatitis C Virus Replicon. <i>Methods in Molecular Biology</i> , 2013, 1030, 93-103.	0.4	3
82	Exploring the importance of zinc binding and steric/hydrophobic factors in novel HCV replication inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1196-1199.	1.0	3
83	Perturbation of Alphavirus and Flavivirus Infectivity by Components of the Bacterial Cell Wall. <i>Journal of Virology</i> , 2022, 96, jvi0006022.	1.5	3
84	Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells. <i>Biochemical Pharmacology</i> , 2015, 96, 190-201.	2.0	2
85	Diterpenoids from Euphorbiaceae with Potent Anti-CHIKV and Anti-HIV Activities: Are these Antiviral Properties Correlated?. <i>Planta Medica</i> , 2013, 79, .	0.7	2
86	In vitro Assay to Assess Efficacy of Potential Antiviral Compounds against Enterovirus D68. <i>Bio-protocol</i> , 2017, 7, e2183.	0.2	2
87	482 IN VITRO COMBINATION THERAPY WITH TEGOBUVIR (GS-9190) IS HIGHLY EFFICIENT IN CURING CELLS FROM HCV REPLICON AND IN DELAYING/PREVENTING THE DEVELOPMENT OF ANTIVIRAL RESISTANCE. <i>Journal of Hepatology</i> , 2011, 54, S197-S198.	1.8	1
88	Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
89	Reply:. <i>Hepatology</i> , 2010, 51, 345-345.	3.6	0
90	A novel class of small molecule inhibitors targeting the chikungunya virus capping machinery with a high barrier to resistance. <i>Access Microbiology</i> , 2019, 1, .	0.2	0